Royal Bank of Canada Buys 375,723 Shares of Athersys, Inc. (ATHX)

Royal Bank of Canada lifted its stake in Athersys, Inc. (NASDAQ:ATHX) by 7,334.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 380,846 shares of the biopharmaceutical company’s stock after buying an additional 375,723 shares during the period. Royal Bank of Canada owned approximately 0.33% of Athersys worth $576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ATHX. Bank of America Corp DE boosted its stake in shares of Athersys by 17.2% in the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,019 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares during the period. SG Americas Securities LLC boosted its stake in shares of Athersys by 329.7% in the second quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 56,345 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Athersys in the second quarter valued at approximately $113,000. Finally, Blair William & Co. IL boosted its stake in shares of Athersys by 708.0% in the second quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 70,804 shares during the period. Institutional investors and hedge funds own 19.48% of the company’s stock.

Shares of Athersys, Inc. (ATHX) opened at $1.87 on Friday. Athersys, Inc. has a 12 month low of $1.02 and a 12 month high of $2.63.

Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). Athersys had a negative return on equity of 113.63% and a negative net margin of 746.04%. The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.96 million. During the same period in the prior year, the company earned ($0.08) earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. equities analysts anticipate that Athersys, Inc. will post -0.25 EPS for the current year.

In other Athersys news, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $2.17, for a total transaction of $32,550.00. Following the completion of the sale, the executive vice president now directly owns 679,416 shares in the company, valued at $1,474,332.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.40% of the stock is owned by corporate insiders.

Several brokerages recently issued reports on ATHX. ValuEngine cut Athersys from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Maxim Group reiterated a “buy” rating and issued a $12.00 price target on shares of Athersys in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.17.

ILLEGAL ACTIVITY NOTICE: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/royal-bank-of-canada-buys-375723-shares-of-athersys-inc-athx.html.

Athersys Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply